TET3 and serous adenocarcinoma: The PFS was significant shorter in advanced stage (III-IV) patients with high TET3 expression (HR = 1.26 (1–1.59), P = 0.048, n = 384, Additional file 2: Figure S2D), but not so significant shorter in high-grade serous adenocarcinoma with early stage (I-II) (HR =3.57 (0.8–16), P = 0.0765, n = 42, Additional file 2: Figure S2E).